BiologicalDrug
CJM-112 clinical trials
Also written CJM112.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
6 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Spartalizumab (2) · Canakinumab (1) · Trametinib (1) · Nazartinib (1) · LCL161 (1)
Studies
Open first, then newest update. How each study uses CJM-112 is read from its arms, and is right about nine times in ten.
Testing it · 6
- Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa PatientsCompletedPhase 2Novartis PharmaceuticalsNCT02421172Written as CJM112
- Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory AcneCompletedPhase 2Novartis PharmaceuticalsNCT02998671Written as CJM112
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedPhase 1Novartis PharmaceuticalsNCT02900664Written as CJM112
- Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple MyelomaCompletedPhase 1Novartis PharmaceuticalsNCT03111992Written as CJM112
- Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe AsthmaCompletedPhase 2Novartis PharmaceuticalsNCT03299686Written as CJM112
- Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in PsoriasisCompletedPhase 1Novartis PharmaceuticalsNCT01828086Written as CJM112
Codes
What other systems call CJM-112 · ClinicalTrials.gg INT016533
- UNII (FDA) F7B2Y24NOECJM-112One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | F7B2Y24NOE | CJM-112 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.